Frédéric Di Fiore

8.1k total citations · 3 hit papers
122 papers, 4.0k citations indexed

About

Frédéric Di Fiore is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Frédéric Di Fiore has authored 122 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Oncology, 36 papers in Pulmonary and Respiratory Medicine and 33 papers in Cancer Research. Recurrent topics in Frédéric Di Fiore's work include Cancer Genomics and Diagnostics (29 papers), Colorectal Cancer Treatments and Studies (20 papers) and Glioma Diagnosis and Treatment (12 papers). Frédéric Di Fiore is often cited by papers focused on Cancer Genomics and Diagnostics (29 papers), Colorectal Cancer Treatments and Studies (20 papers) and Glioma Diagnosis and Treatment (12 papers). Frédéric Di Fiore collaborates with scholars based in France, Italy and United States. Frédéric Di Fiore's co-authors include Pierre Michel, Thierry Frébourg, Jean‐Christophe Sabourin, A. Montagnoli, Esther Eytan, Avram Hershko, Andrea C. Carrano, Giulio Draetta, Michele Pagano and Richard Sesboüé and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Frédéric Di Fiore

113 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

2007 621 citations Frédéric Di Fiore, Marie‐Pierre Galais et al. British Journal of Cancer profile →
Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation

1999 491 citations Frédéric Di Fiore et al. profile →
Selective STING stimulation in dendritic cells primes antitumor T cell responses

2023 103 citations Aurore Bochnakian, Caroline Hoffmann et al. Science Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Frédéric Di Fiore France	32	2.1k	1.4k	945	735	593	122	4.0k
Shelia M. Violette United States	37	1.2k 0.6×	2.1k 1.5×	747 0.8×	1.2k 1.6×	625 1.1×	71	5.2k
Emily Chan United States	29	2.1k 1.0×	1.7k 1.2×	746 0.8×	802 1.1×	436 0.7×	90	4.8k
Giuliana Salvatore Italy	36	2.0k 1.0×	2.2k 1.6×	459 0.5×	380 0.5×	596 1.0×	83	5.3k
Philippe Rochaix France	37	1.9k 0.9×	1.3k 0.9×	1.0k 1.1×	593 0.8×	432 0.7×	96	4.0k
Stefania Bellone United States	41	2.4k 1.2×	1.8k 1.3×	1.4k 1.5×	571 0.8×	761 1.3×	155	5.4k
Leonhard Müllauer Austria	39	1.3k 0.6×	1.8k 1.3×	1.2k 1.2×	592 0.8×	530 0.9×	198	5.3k
Paulette Mhawech‐Fauceglia United States	35	2.0k 1.0×	1.9k 1.4×	1.6k 1.7×	676 0.9×	689 1.2×	126	5.0k
Reinhard Horvat Austria	40	1.4k 0.7×	1.8k 1.3×	544 0.6×	474 0.6×	1.0k 1.7×	106	4.2k
Lukas J.A.C. Hawinkels Netherlands	31	2.1k 1.0×	1.9k 1.3×	1.6k 1.7×	590 0.8×	895 1.5×	99	4.8k
Ian Kasman United States	20	1.5k 0.7×	2.5k 1.8×	2.1k 2.2×	331 0.5×	1.0k 1.8×	26	5.3k

Countries citing papers authored by Frédéric Di Fiore

Since Specialization

Citations

This map shows the geographic impact of Frédéric Di Fiore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédéric Di Fiore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédéric Di Fiore more than expected).

Fields of papers citing papers by Frédéric Di Fiore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédéric Di Fiore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédéric Di Fiore. The network helps show where Frédéric Di Fiore may publish in the future.

Co-authorship network of co-authors of Frédéric Di Fiore

This figure shows the co-authorship network connecting the top 25 collaborators of Frédéric Di Fiore. A scholar is included among the top collaborators of Frédéric Di Fiore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frédéric Di Fiore. Frédéric Di Fiore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Spinelli, Lionel, Lionel Chasson, Frédéric Di Fiore, et al.. (2025). Characterization of the immune landscape in healthy mouse prostate and during prostate cancer progression. OncoImmunology. 14(1). 2562220–2562220.

Ruminy, Philippe, et al.. (2025). Prognostic value of circulating HER2 extracellular domain in patients with HER2-positive metastatic breast carcinoma treated with TDM-1 (trastuzumab emtansine). Clinical & Translational Oncology. 28(2). 711–718. 1 indexed citations

Ducreux, Michel, Yves Rinaldi, Frédéric Di Fiore, et al.. (2025). PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma. Journal of Clinical Oncology. 43(20). 2255–2264. 3 indexed citations

Robert, F., Mina Ha, Alessandra Cuomo, et al.. (2024). Placental growth factor modulates endothelial NO production and exacerbates experimental hepatopulmonary syndrome. JHEP Reports. 7(3). 101297–101297. 1 indexed citations

Gillibert, André, et al.. (2024). Where do we stand with screening for colorectal cancer and advanced adenoma based on serum protein biomarkers? A systematic review. Molecular Oncology. 18(11). 2629–2648.

Bouhier‐Leporrier, Karine, et al.. (2024). Relative dose intensity of first-line triplet chemotherapy in metastatic colorectal cancer. Digestive and Liver Disease. 57(1). 30–37. 2 indexed citations

Marguet, Florent, et al.. (2024). The clinical impact of EGFR alterations in elderly glioblastoma patients: results from a real-life cohort. Journal of Neuro-Oncology. 171(3). 619–628. 1 indexed citations

Alexandru, Cristina, Isabelle Tennevet, Olivier Langlois, et al.. (2024). Prognostic value of circulating short-length DNA fragments in unresected glioblastoma patients. Translational Oncology. 42. 101897–101897. 1 indexed citations

Bochnakian, Aurore, Caroline Hoffmann, Philémon Sirven, et al.. (2023). Selective STING stimulation in dendritic cells primes antitumor T cell responses. Science Immunology. 8(79). eabn6612–eabn6612. 103 indexed citations breakdown →

10.

Gorvel, Laurent, Sonia Pastor, Clara Degos, et al.. (2023). Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors. Journal for ImmunoTherapy of Cancer. 11(5). e006348–e006348. 13 indexed citations

11.

Beaussire, Ludivine, Marianne Leheurteur, Cécile Guillemet, et al.. (2023). Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma. BMC Cancer. 23(1). 1061–1061. 5 indexed citations

12.

Tron, Camille, F. Lemaı̂tre, Thierry Lecomte, et al.. (2022). 449TiP Evaluation of regorafenib treatment PERSOnalization based on therapeutic drug monitoring in patients with metastatic colorectal cancer (mCRC): RePERSO study. Annals of Oncology. 33. S739–S740. 1 indexed citations

13.

Gilard, Vianney, Florent Marguet, Maxime Fontanilles, et al.. (2021). Integrative Metabolomics Reveals Deep Tissue and Systemic Metabolic Remodeling in Glioblastoma. Cancers. 13(20). 5157–5157. 14 indexed citations

14.

Fontanilles, Maxime, et al.. (2021). Place des biopsies liquides dans le diagnostic et la caractérisation moléculaire des cancers du sein. Bulletin du Cancer. 108(11). 11S46–11S54.

15.

Sefrioui, David, Céline Savoye‐Collet, Ludivine Beaussire, et al.. (2020). 1007P cfDNA and ctDNA variations are predictive of disease progression to conventional transarterial chemoembolization (cTACE) in patients with hepatocellular carcinoma (HCC). Annals of Oncology. 31. S698–S698. 1 indexed citations

16.

Laurent, Lucie, David Sefrioui, Aurélie Parzy, et al.. (2018). CA19.9 decrease >15% is a predictor of favourable outcome in patients treated for advanced pancreatic carcinoma: analysis of two independent cohorts. HPB. 21(5). 582–588. 15 indexed citations

17.

Roncagalli, Romain, Claude Grégoire, Stéphane Audebert, et al.. (2016). The scaffolding function of the RLTPR protein explains its essential role for CD28 co-stimulation in mouse and human T cells. The Journal of Experimental Medicine. 213(11). 2437–2457. 60 indexed citations

18.

Fiore, Frédéric Di, Richard Sesboüé, Pierre Michel, Jean‐Christophe Sabourin, & Thierry Frébourg. (2010). Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. British Journal of Cancer. 103(12). 1765–1772. 53 indexed citations

19.

Hebbar, Mohamed, Frédéric Di Fiore, Thierry Conroy, et al.. (2007). Assessment of Baseline Clinical Predictive Factors of Response to Cetuximab-Irinotecan in Patients with Irinotecan-Refractory Metastatic Colorectal Cancer. Oncology. 73(3-4). 185–191. 8 indexed citations

20.

Michel, Pierre, et al.. (2004). Colorectal cancer with non-resectable synchronous metastases: should the primary tumor be resected?. Gastroentérologie Clinique et Biologique. 28(5). 434–437. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact